New advancements in Cold Agglutinin Disease treatments promise improved patient outcomes and market growth, driving innovation and investment in the sector.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar ...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

The GALAD algorithm combines gender (biological sex), age, α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction ...

In October 2024, Recordati reached an agreement with Sanofi to acquire the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease, a rare B-cell ...

In October 2024, Recordati reached an agreement with Sanofi to acquire the worldwide rights to Enjaymo, the only approved ...

Images in paediatrics: Greenish-yellow fluorescence of scalp kerion celsi using Wood’s lamp (22 August, 2024) ...

A recent study highlights the potential benefits of oral semaglutide in managing type 2 diabetes mellitus (T2DM) for patients ...